KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $15.6 million.

  • Nektar Therapeutics' Accounts Payables rose 8145.04% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year increase of 8145.04%. This contributed to the annual value of $11.6 million for FY2024, which is 1738.42% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Accounts Payables is $15.6 million, which was up 8145.04% from $14.3 million recorded in Q2 2025.
  • Nektar Therapeutics' Accounts Payables' 5-year high stood at $23.7 million during Q3 2021, with a 5-year trough of $2.6 million in Q2 2023.
  • For the 5-year period, Nektar Therapeutics' Accounts Payables averaged around $11.6 million, with its median value being $11.6 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first plummeted by 7878.67% in 2023, then soared by 16085.77% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Accounts Payables (Quarter) stood at $9.7 million in 2021, then surged by 33.17% to $13.0 million in 2022, then decreased by 24.13% to $9.8 million in 2023, then grew by 17.38% to $11.6 million in 2024, then surged by 34.63% to $15.6 million in 2025.
  • Its last three reported values are $15.6 million in Q3 2025, $14.3 million for Q2 2025, and $17.8 million during Q1 2025.